{"id":"W4393098859","doi":"10.1016/j.ejca.2024.113958","title":"A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with Perjeta® (pertuzumab) in patients with HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Pertuzumab; Biosimilar; Immunogenicity; Pharmacokinetics; Medicine; Double blind; Pharmacology; Internal medicine; Trastuzumab; Placebo; Immunology; Antibody; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002073707,0.001543283,0.004048033,0.0006085186,0.0006885887,0.001021682,0.00110515,0.00181217,0.005411132],"category_scores_gemma":[0.002034912,0.0009337355,0.001499869,0.0009008702,0.002653788,0.001186903,0.0005975124,0.003671405,0.001086362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008832891,"about_ca_system_score_gemma":0.002264114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001256811,"about_ca_topic_score_gemma":0.001779092,"domain_scores_codex":[0.9990991,0.0004504905,0.00004903582,0.0001771066,0.00006644963,0.000157746],"domain_scores_gemma":[0.997905,0.0006133992,0.0003635368,0.0002924202,0.0001628428,0.0006627296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9699392,0.01877613,0.0005450153,0.0001707592,0.0003244911,0.00002959247,0.00007132353,0.0002941253,0.002812328,0.0001081265,0.0003341622,0.0065949],"study_design_scores_gemma":[0.884693,0.1129655,0.00111145,0.000008148536,0.0001693052,0.00002177775,0.00001968349,0.000211243,0.0003823023,0.00008882087,0.0003187299,0.00001006029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863788,0.001104566,0.001390921,0.0004167308,0.000373229,0.007525932,0.0009558796,0.0001595755,0.001694415],"genre_scores_gemma":[0.9778557,0.001232335,0.003276371,0.001409721,0.0004881634,0.01056715,0.001301787,0.00005701682,0.003811692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005411132,"threshold_uncertainty_score":0.01810199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03121014927277414,"score_gpt":0.3622070905831796,"score_spread":0.3309969413104055,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}